Drug intelligence / Profile preview

GRK008

Development stage: Preclinical
Lead developer: Suzhou Glanke Medical Technology
Modality: Small Molecules
Administration: Oral

Overview

GRK008 is an investigational oral therapeutic being developed by Suzhou Glanke Medical Technology (GrandKol) for the treatment of traumatic brain injury (TBI), specifically during the chronic or rehabilitation phase. The drug is designed to promote nerve regeneration and repair functions following brain injuries resulting from car accidents, sports, falls, or battlefield blasts. Unlike acute treatments that focus on limiting immediate damage, GRK008 aims to restore neurological function by facilitating the recovery of neural pathways. It is currently in development and is administered as an oral tablet.

Targets

GRK2 (G protein-coupled receptor kinase 2)

Beyond the preview

Go deeper on GRK008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRK008.

Explore the full profile